Cargando…

Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation

BACKGROUND: Bloodstream infections (BSIs) are an important cause of morbidity and mortality in hospitalized patients. We evaluate incidence of community- and hospital-onset BSI rates and outcomes before and during the SARS-CoV-2 pandemic. METHODS: We conducted a retrospective cohort study evaluating...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Karri A., Puzniak, Laura A., Yu, Kalvin C., Finelli, Lyn, Moise, Pamela, Ai, ChinEn, Watts, Janet A., Gupta, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651895/
https://www.ncbi.nlm.nih.gov/pubmed/36368931
http://dx.doi.org/10.1186/s12879-022-07810-8
_version_ 1784828330710663168
author Bauer, Karri A.
Puzniak, Laura A.
Yu, Kalvin C.
Finelli, Lyn
Moise, Pamela
Ai, ChinEn
Watts, Janet A.
Gupta, Vikas
author_facet Bauer, Karri A.
Puzniak, Laura A.
Yu, Kalvin C.
Finelli, Lyn
Moise, Pamela
Ai, ChinEn
Watts, Janet A.
Gupta, Vikas
author_sort Bauer, Karri A.
collection PubMed
description BACKGROUND: Bloodstream infections (BSIs) are an important cause of morbidity and mortality in hospitalized patients. We evaluate incidence of community- and hospital-onset BSI rates and outcomes before and during the SARS-CoV-2 pandemic. METHODS: We conducted a retrospective cohort study evaluating patients who were hospitalized for ≥ 1 day with discharge or death between June 1, 2019, and September 4, 2021, across 271 US health care facilities. Community- and hospital-onset BSI and related outcomes before and during the SARS-CoV-2 pandemic, including intensive care admission rates, and overall and ICU-specific length of stay (LOS) was evaluated. Bivariate correlations were calculated between the pre-pandemic and pandemic periods overall and by SARS-CoV-2 testing status. RESULTS: Of 5,239,692 patient admissions, there were 20,113 community-onset BSIs before the pandemic (11.2/1000 admissions) and 39,740 (11.5/1000 admissions) during the pandemic (P ≤ 0.0062). Corresponding rates of hospital-onset BSI were 2,771 (1.6/1000 admissions) and 6,864 (2.0/1000 admissions; P < 0.0062). Compared to the pre-pandemic period, rates of community-onset BSI were higher in patients who tested negative for SARS-CoV-2 (15.8/1000 admissions), compared with 9.6/1000 BSI admissions among SARS-CoV-2-positive patients. Compared with patients in the pre-pandemic period, SARS-CoV-2-positive patients with community-onset BSI experienced greater ICU admission rates (36.6% vs 32.8%; P < 0.01), greater ventilator use (10.7% vs 4.7%; P < 0.001), and longer LOS (12.2 d vs 9.1 d; P < 0.001). Rates of hospital-onset BSI were higher in the pandemic vs the pre-pandemic period (2.0 vs 1.5/1000; P < 0.001), with rates as high a 7.3/1000 admissions among SARS-CoV-2-positive patients. Compared to the pre-pandemic period, SARS-CoV-2-positive patients with hospital-onset BSI had higher rates of ICU admission (72.9% vs 55.4%; P < 0.001), LOS (34.8 d vs 25.5 d; P < 0.001), and ventilator use (52.9% vs 21.5%; P < 0.001). Enterococcus species, Staphylococcus aureus, Klebsiella pneumoniae, and Candida albicans were more frequently detected in the pandemic period. CONCLUSIONS AND RELEVANCE: This nationally representative study found an increased risk of both community-onset and hospital-onset BSI during the SARS-CoV-2 pandemic period, with the largest increased risk in hospital-onset BSI among SARS-CoV-2-positive patients. SARS-CoV-2 positivity was associated with worse outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07810-8.
format Online
Article
Text
id pubmed-9651895
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96518952022-11-14 Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation Bauer, Karri A. Puzniak, Laura A. Yu, Kalvin C. Finelli, Lyn Moise, Pamela Ai, ChinEn Watts, Janet A. Gupta, Vikas BMC Infect Dis Research BACKGROUND: Bloodstream infections (BSIs) are an important cause of morbidity and mortality in hospitalized patients. We evaluate incidence of community- and hospital-onset BSI rates and outcomes before and during the SARS-CoV-2 pandemic. METHODS: We conducted a retrospective cohort study evaluating patients who were hospitalized for ≥ 1 day with discharge or death between June 1, 2019, and September 4, 2021, across 271 US health care facilities. Community- and hospital-onset BSI and related outcomes before and during the SARS-CoV-2 pandemic, including intensive care admission rates, and overall and ICU-specific length of stay (LOS) was evaluated. Bivariate correlations were calculated between the pre-pandemic and pandemic periods overall and by SARS-CoV-2 testing status. RESULTS: Of 5,239,692 patient admissions, there were 20,113 community-onset BSIs before the pandemic (11.2/1000 admissions) and 39,740 (11.5/1000 admissions) during the pandemic (P ≤ 0.0062). Corresponding rates of hospital-onset BSI were 2,771 (1.6/1000 admissions) and 6,864 (2.0/1000 admissions; P < 0.0062). Compared to the pre-pandemic period, rates of community-onset BSI were higher in patients who tested negative for SARS-CoV-2 (15.8/1000 admissions), compared with 9.6/1000 BSI admissions among SARS-CoV-2-positive patients. Compared with patients in the pre-pandemic period, SARS-CoV-2-positive patients with community-onset BSI experienced greater ICU admission rates (36.6% vs 32.8%; P < 0.01), greater ventilator use (10.7% vs 4.7%; P < 0.001), and longer LOS (12.2 d vs 9.1 d; P < 0.001). Rates of hospital-onset BSI were higher in the pandemic vs the pre-pandemic period (2.0 vs 1.5/1000; P < 0.001), with rates as high a 7.3/1000 admissions among SARS-CoV-2-positive patients. Compared to the pre-pandemic period, SARS-CoV-2-positive patients with hospital-onset BSI had higher rates of ICU admission (72.9% vs 55.4%; P < 0.001), LOS (34.8 d vs 25.5 d; P < 0.001), and ventilator use (52.9% vs 21.5%; P < 0.001). Enterococcus species, Staphylococcus aureus, Klebsiella pneumoniae, and Candida albicans were more frequently detected in the pandemic period. CONCLUSIONS AND RELEVANCE: This nationally representative study found an increased risk of both community-onset and hospital-onset BSI during the SARS-CoV-2 pandemic period, with the largest increased risk in hospital-onset BSI among SARS-CoV-2-positive patients. SARS-CoV-2 positivity was associated with worse outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07810-8. BioMed Central 2022-11-11 /pmc/articles/PMC9651895/ /pubmed/36368931 http://dx.doi.org/10.1186/s12879-022-07810-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bauer, Karri A.
Puzniak, Laura A.
Yu, Kalvin C.
Finelli, Lyn
Moise, Pamela
Ai, ChinEn
Watts, Janet A.
Gupta, Vikas
Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title_full Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title_fullStr Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title_full_unstemmed Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title_short Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation
title_sort epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the sars-cov-2 pandemic: a multicenter evaluation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651895/
https://www.ncbi.nlm.nih.gov/pubmed/36368931
http://dx.doi.org/10.1186/s12879-022-07810-8
work_keys_str_mv AT bauerkarria epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT puzniaklauraa epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT yukalvinc epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT finellilyn epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT moisepamela epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT aichinen epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT wattsjaneta epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation
AT guptavikas epidemiologyandoutcomesofculturepositivebloodstreampathogenspriortoandduringthesarscov2pandemicamulticenterevaluation